These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7762722)

  • 41. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.
    De Wals P; Zhou Z
    Pediatr Infect Dis J; 2017 Jul; 36(7):e203-e207. PubMed ID: 28027288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
    Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
    Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of invasive meningococcal disease in university students in England and optimal strategies for protection using MenACWY vaccine.
    Mandal S; Campbell H; Ribeiro S; Gray S; Carr T; White J; Ladhani SN; Ramsay ME
    Vaccine; 2017 Oct; 35(43):5814-5818. PubMed ID: 28928076
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention of meningococcal infections in the first 2 years of life.
    Woods CR
    Pediatr Ann; 2013 Aug; 42(8):164-71. PubMed ID: 23910030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention.
    Atkinson B; Gandhi A; Balmer P
    Pharmacotherapy; 2016 Aug; 36(8):880-92. PubMed ID: 27332671
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meningococcal C conjugate age-dependant long-term loss of effectiveness.
    Garrido-Estepa M; Nuñez OG; León-Gómez I; Cano R; Herruzo R
    Vaccine; 2015 May; 33(19):2221-2227. PubMed ID: 25819711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictors of meningococcal vaccine uptake in university and college students: a systematic review and meta-analysis.
    Whisnant J; Martin-Kerry J; Flett L; Knapp P
    J Am Coll Health; 2022; 70(6):1738-1753. PubMed ID: 33048644
    [No Abstract]   [Full Text] [Related]  

  • 49. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil.
    de Soarez PC; Sartori AM; de Andrade Lagoa Nóbrega L; Itria A; Novaes HM
    Value Health; 2011 Dec; 14(8):1019-27. PubMed ID: 22152170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
    Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
    Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.
    Richmond P; Borrow R; Miller E; Clark S; Sadler F; Fox A; Begg N; Morris R; Cartwright K
    J Infect Dis; 1999 Jun; 179(6):1569-72. PubMed ID: 10228085
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Meningococcal vaccine. Editorial].
    Gendrel D; Cohen R
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S47-8. PubMed ID: 22883365
    [No Abstract]   [Full Text] [Related]  

  • 54. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination.
    Pérez-Breva L; Abad-Torreblanca R; Martínez-Beneito MÁ; Puig-Barberà J; Alemán-Sánchez S; Morant-Talamante N; Sastre-Cantón M; Vázquez-Moreno JA; Díez-Domingo J
    Vaccine; 2017 May; 35(22):2949-2954. PubMed ID: 28438407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016.
    Soeters HM; Whaley M; Alexander-Scott N; Kanadanian KV; MacNeil JR; Martin SW; McNamara LA; Sicard K; Vanner C; Vuong J; Wang X; Bandy U; Patel M;
    Clin Infect Dis; 2017 Apr; 64(8):1115-1122. PubMed ID: 28158417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Meningococcal vaccine for adolescents and college freshmen.
    FDA Consum; 2005; 39(5):4. PubMed ID: 16421984
    [No Abstract]   [Full Text] [Related]  

  • 59. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Boulianne N; De Serres G
    Pediatr Infect Dis J; 2011 Jul; 30(7):566-9. PubMed ID: 21326136
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serogroup A meningococcal conjugate vaccines in Africa.
    Kristiansen PA; Jørgensen HJ; Caugant DA
    Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.